Related Experiment Videos
Summary
Bacillus Calmette-Guerin immunotherapy significantly reduced tumor recurrence in bladder cancer patients. A simple skin test predicted treatment response, aiding in personalized immunotherapy strategies for transitional cell carcinoma.
Area of Science:
- Urology
- Immunotherapy
- Oncology
Background:
- Transitional cell carcinoma (TCC) of the bladder is a significant health concern.
- Intravesical and percutaneous Bacillus Calmette-Guerin (BCG) immunotherapy offers a treatment option for TCC.
- Evaluating BCG's efficacy and predictive markers is crucial for optimizing patient outcomes.
Observation:
- A randomized controlled trial compared BCG immunotherapy with control in 57 TCC patients.
- BCG treatment resulted in a self-limited cystitis and one case of hydronephrosis.
- Patient follow-up ranged from 3 to 30 months.
Findings:
- BCG immunotherapy significantly reduced tumor recurrence rates compared to controls (21% vs. 50%, p=0.027).
- The disease-free interval was significantly prolonged in patients receiving BCG (p=0.014).
- A positive conversion of the purified protein derivative (PPD) skin test indicated a favorable response to BCG, with significantly lower recurrence rates (6% vs. 38%, p=0.022).
Implications:
- BCG immunotherapy is an effective treatment for transitional cell carcinoma of the bladder, reducing recurrence and prolonging disease-free survival.
- The PPD skin test can serve as a valuable predictive marker for BCG immunotherapy response.
- BCG offers a viable treatment option for patients with Stage B TCC and carcinoma in situ, including those unsuitable for cystectomy.